非酒精性脂肪性肝病患者血红蛋白水平变化及其临床意义

doi:10.3969/j.issn.1672-5069.2021.01.011

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (1): 39-42.doi: 10.3969/j.issn.1672-5069.2021.01.011

非酒精性脂肪性肝病患者血红蛋白水平变化及其临床意义

陈光榆, 王鸿, 王耀晟, 张熙, 张伟, 曾静, 沈峰, 胡颖, 范建高

200092 上海市上海交通大学医学院附属新华医院临床研究与创新中心(陈光榆,王耀晟,张熙,张伟);
消化内科(曾静,沈峰,范建高);
崇明分院消化内科(王鸿,胡颖)

出版日期:2021-01-10 发布日期:2021-01-19
通讯作者: 陈光榆,女,43岁,医学博士,主治医师。E-mail:chenguangyu@xinhuamed.com.cn
通讯作者:胡颖,E-mail:xyhuying@qq.com
作者简介:陈光榆,女,43岁,医学博士,主治医师。E-mail:chenguangyu@xinhuamed.com.cn
基金资助:
上海交通大学医学院附属新华医院院级临床研究培育基金项目(编号:17CSK04)

Blood hemoglobin levels for risk of individuals apt to have nonalcoholic fatty liver disease risk

Chen Guangyu, Wang Hong, Wang Yaoshen, et al

Department of Gastroenterology, Xinhua Hospital Affricated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, Shanghai, China

Online:2021-01-10 Published:2021-01-19

摘要/Abstract

摘要： 目的探讨血红蛋白升高与非酒精性脂肪性肝病(NAFLD)发生风险的相关性。方法利用1995年～1996年宝钢职工体检资料,收集血糖、血脂和血红蛋白等指标,对6540例无脂肪肝人群随访6年,分析基线血红蛋白水平与NAFLD发生风险之间的相关性。结果在随访过程中,106例基线贫血患者新发NAFLD 2例(1.9%),5884例基线血红蛋白正常者新发645例(11.0%),550例基线血红蛋白升高患者新发116例(21.1%);Cox单因素回归分析结果显示不同血红蛋白水平者NAFLD发生率不同(血红蛋白升高组与贫血组比,HR=11.18,95% CI:2.76～45.23,P=0.001;血红蛋白正常组与贫血组比,HR=5.81,95% CI:1.45～23.28,P=0.013);经Cox多因素回归分析结果显示男性(HR=1.465,95% CI:1.114～1.928,P=0.006)、体质指数(HR=1.298,95% CI:1.259～1.320,P<0.001)、高甘油三酯血症(HR=1.781,95% CI:1.533～2.068,P<0.001)和血红蛋白水平(HR=1.008,95% CI:1.002～1.015 P=0.014)是影响NAFLD发生的独立危险因素。结论血红蛋白升高与NAFLD发病相关,早期筛查Hb有助于风险提示,其相关机制值得进一步研究。

关键词: 非酒精性脂肪性肝病, 血红蛋白, 贫血, 危险因素

Abstract: Objective To explore the relationship between high blood hemoglobin levels and the risk of non-alcoholic fatty liver disease (NAFLD). Methods 6540 NAFLD-free participants at physical examination in Baoshan Steel were recruited and their data including blood glucose, blood lipids and hemoglobin in 1995 to 1996 were collected. We explored the baseline blood hemoglobin level longitudinal associations with NAFLD risk throughout 6 years. Results During follow-up, 2 (11.7%) cases of NAFLD developed among 106 patients with anemia, 645(11.0%) NAFLD in 5884 participants with normal hemoglobin, and 116 (21.1%) NAFLD in 550 patients with high blood hemoglobin; Cox univariate analysis showed that hemoglobin level was related to the risk of NAFLD (high hemoglobin group vs. anemia group, HR=11.18, 95% CI: 2.76-45.23, P=0.001; normal hemoglobin vs. anemia group, HR=5.81, 95% CI: 1.45-23.28, P=0.013); Cox multivariate analysis showed that male (HR=1.465,95% CI:1.114-1.928,P=0.006), BMI (HR=1.298,95% CI:1.259-1.320,P<0.001), hypertriglyceridemia (HR=1.781, 95% CI: 1.533-2.068, P<0.001) and hemoglobin (HR=1.008, 95% CI: 1.002-1.015, P=0.014) were the independent risk factors for occurrence of NAFLD.Conclusion High blood hemoglobin levels is correlated with NAFLD risk. The potential value of early screening blood hemoglobin and intervention for NAFLD deserve further study.

Key words: Nonalcoholic fatty liver disease, Hemoglobin, Anemia, Risk factors

陈光榆, 王鸿, 王耀晟, 张熙, 张伟, 曾静, 沈峰, 胡颖, 范建高. 非酒精性脂肪性肝病患者血红蛋白水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 39-42.

Chen Guangyu, Wang Hong, Wang Yaoshen, et al. Blood hemoglobin levels for risk of individuals apt to have nonalcoholic fatty liver disease risk[J]. Journal of Practical Hepatology, 2021, 24(1): 39-42.

参考文献

[1] Bai CH, Wu MS, Owaga E, et al. Relationship between hemoglobin levels and risk for suspected non-alcoholic fatty liver in Taiwanese adults. Chin J Physiol, 2014, 57(5):286-294.
[2] 孙长贵, 曾静, 孙婉璐, 等. 非酒精性脂肪性肝病患者估算的肾小球滤过率的变化及其影响因素分析. 实用肝脏病杂志, 2017, 20(2):165-170.
[3] Xu L, Xu CF, Yu CH, et al. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut, 2009, 58(12):1706-1707.
[4] Yu CH, Xu CF, Xu L, et al. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol, 2012, 56(1):241-247.
[5] Yang W, Huang HY, Wang YZ, et al. High red blood cell distribution width is closely associated with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol, 2014, 26(2):174-178.
[6] 张帆, 苏淑贞, 卓仲芬, 等. 106例非酒精性脂肪肝患者血液流变学分析. 实用肝脏病杂志, 2010, 13(3):196-197.
[7] Tan PC, Chai JN, Ling LP, et al. Maternal hemoglobin level and red cell indices as predictors of gestational diabetes in a multi-ethnic Asian population. Clin Exp Obstet Gynecol, 2011, 38(2):150-154.
[8] Tanoglu A, Kara M. Nonalcoholic fatty liver disease-related cardiovascular risk: Is there an association with blood hemoglobin levels? Eur J Gastroenterol Hepatol, 2015, 27(10):1126-1129.
[9] Ahmed U, Latham PS, Oates PS. Interactions between hepatic iron and lipid metabolism with possible relevance to steatohepatitis. World J Gastroenterol, 2012, 18(34):4651-4658.
[10] Britton LJ, Subramaniam VN, Crawford DH. Iron and non-alcoholic fatty liver disease. World J Gastroenterol, 2016, 22(36):8112-8122.
[11] Datz C, Müller E, Aigner E. Iron overload and non-alcoholic fatty liver disease. Minerva Endocrinol, 2017, 42(2):173-183.
[12] Ryan JD, Armitage AE, Cobbold JF, et al. Hepatic iron is the major determinant of serum ferritin in NAFLD patients. Liver Int, 2018, 38(1):164-173.
[13] Buzzetti E, Petta S, Manuguerra R, et al. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. Liver Int, 2019, 39(7):1325-1334.
[14] Fujita N, Miyachi H, Tanaka H, et al. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev, 2009, 18(2):424-432.
[15] Zimmermann A, Zimmermann T, Schattenberg J, et al. Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. Eur J Intern Med, 2011, 22(3):305-310.

非酒精性脂肪性肝病患者血红蛋白水平变化及其临床意义

Blood hemoglobin levels for risk of individuals apt to have nonalcoholic fatty liver disease risk

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	荣爱梅, 张超, 吴慧丽. 西罗莫司对高脂饮食诱导的NAFLD大鼠外周血Treg/Th17细胞的影响[J]. 实用肝脏病杂志, 2021, 24(1): 10-13.
[2]	夏淑晶, 张莉莉, 张秀梅, 赵根宝, 周松伟, 罗欲承, 陈红芹, 王子华, 成凤干, 范建高. 非酒精性脂肪性肝病患者血清SDC4变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 43-46.
[3]	魏秀琴, 闫晓霞, 石国荣, 赵宏伟, 李基寿. 阿托伐他汀联合硫普罗宁治疗非酒精性脂肪性肝病患者疗效初步研究[J]. 实用肝脏病杂志, 2021, 24(1): 47-50.
[4]	梁小丽, 邝继孙, 刘秋莉, 符弟. 非诺贝特联合热量限制饮食治疗非酒精性脂肪性肝病合并2型糖尿病患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 51-54.
[5]	赵晓春, 钟庆, 刘书宏, 梁尘格, 郭熙清, 温林. 非酒精性脂肪性肝病并发2型糖尿病患者血尿酸水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(1): 55-58.
[6]	李钊, 黄赞松, 李繁. 非诺贝特联合双环醇治疗非酒精性脂肪性肝病患者肝组织PPARγ₂mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 59-62.
[7]	陈金玉, 郭晓霞, 钟晓妮. 二甲双胍联合双歧杆菌三联活菌胶囊治疗非酒精性脂肪性肝病患者疗效及血清IRS1、IRS2和GLUT4的变化[J]. 实用肝脏病杂志, 2021, 24(1): 63-66.
[8]	李俊缨, 周玲, 陈金军. 非酒精性脂肪性肝病高危人群:监测与防治[J]. 实用肝脏病杂志, 2020, 23(5): 612-614.
[9]	叶俊钊, 钟碧慧. 非酒精性脂肪性肝病合并代谢并发症患者规范治疗与管理[J]. 实用肝脏病杂志, 2020, 23(5): 615-618.
[10]	方奕, 陈毅雄, 裴冬萍, 操银针. 恩替卡韦联合复方嗜酸乳杆菌治疗CHB合并NAFLD患者疗效及其对血清相关酶系的影响[J]. 实用肝脏病杂志, 2020, 23(5): 634-637.
[11]	胡亦懿, 翟英姬, 梅迪华, 张志侨, 罗晓亮, 黄燕峰, 杜国平. 余甘子提取物对非酒精性脂肪性肝病大鼠外周血Treg细胞及肝组织LXRα/FAS通路表达的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 488-491.
[12]	侯光华, 胡启江, 徐美华, 朱绍咏, 黄波. 多烯磷脂酰胆碱联合二甲双胍和非诺贝特治疗NAFLD患者血清Pygo2和血脂水平变化^*[J]. 实用肝脏病杂志, 2020, 23(4): 528-531.
[13]	周娜, 蒋磊, 吴冰冰. 阿托伐他汀治疗NAFLD患者对肝脂肪变和外周血Treg/Th17细胞的影响^*[J]. 实用肝脏病杂志, 2020, 23(4): 532-535.
[14]	吴鹏波,宋琪,俞媛洁,郭一天,饶倩,柴红,谭诗云. 姜黄素对非酒精性脂肪肝细胞模型保护作用以及机制研究[J]. 实用肝脏病杂志, 2020, 23(3): 324-327.
[15]	唐晓飞,钟梦菊,沈海娟. 柚皮素脂质体对非酒精性脂肪性肝病大鼠脂质代谢的影响及机制研究[J]. 实用肝脏病杂志, 2020, 23(3): 328-331.